A study reveals 24.7% of anti-cancer drugs saw no price drop under NPPA's trade margin rationalisation, as expensive MNC brands retained earlier MRPs. New Delhi: The Centre’s decision to cap trade margins on 137 non-scheduled anti-cancer drugs has reduced the maximum retail prices (MRPs) of 484 of 643 listed medicine packs, but left nearly one.